Rhythm Pharmaceuticals, Inc.
RYTM
Rang în acțiuni
#3016
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Preț acțiune
$88.37
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$6.08B
Schimbare (1 zi)
2.55%
Schimbare (1 an)
-21.37%
Țară
US
Tranzacționează Rhythm Pharmaceuticals, Inc. (RYTM)
Categorie
Healthcare
Raport P/S pentru Rhythm Pharmaceuticals, Inc. (RYTM)
Raport P/S la data de October 2026 TTM: 24.79
Conform celor mai recente rapoarte financiare și prețului acțiunilor Rhythm Pharmaceuticals, Inc., raportul P/S actual (TTM) este 24.79. La sfârșitul anului 2023, compania avea un P/S de 34.24.
Istoricul raportului P/S pentru Rhythm Pharmaceuticals, Inc. din 2012 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 24.79 | -5.52% |
| 2024 | 26.24 | -23.37% |
| 2023 | 34.24 | -46.67% |
| 2022 | 64.21 | -59.09% |
| 2021 | 156.95 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.02 | -59.57% |
US
|
|
| 40.55 | 63.57% |
US
|
|
| 3.96 | -84.02% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -59.07% |
NL
|
